By Dr Charlotte Rose Lemech

Conference Abstracts

Lee DH; Roohullah A; Cho BC; Lee S-H; Lemech C; De Souza P; Millward M; Choi J; Park KE; Kim E; Kim NY; Shin YK; Han J-Y, 2022, 'A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1096 - S1096, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1320

Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Alvarez EC; Yang JC-H; Ascierto PA; Pulla MP; Freeman D; Song X; Gainer SD; Mitchell P; Achour I; Subramaniam DS; Im S-A, 2022, 'Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. CT016 - CT016, http://dx.doi.org/10.1158/1538-7445.am2022-ct016

Lee DH; Roohullah A; Cho BC; Lemech CR; de Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin YOUNGKEE; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3105 - 3105, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3105

Strickler JH; Satake H; Hollebecque A; Sunakawa Y; Tomasini P; Bajor DL; Schuler MH; Yaeger R; George TJ; Garrido-Laguna I; Coveler AL; Vincent MD; Falchook GS; Burns TF; Rha SY; Lemech CR; Juric D; Jafarinasabian P; Tran Q; Hong DS, 2022, 'First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 360490 - 360490, http://dx.doi.org/10.1200/jco.2022.40.36_suppl.360490

Markman B; Day D; Park JJW; Coward J; Bishnoi S; Kotasek D; Eek R; Brown MP; Lemech C; Kuo J; Prawira A; Strother R; Zhang Q; Wang L; Chen R; Ma Y; Qin Z; Tse A, 2020, 'Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S722 - S722, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1177

Back to profile page